Ken Griffin Absci Corp Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Absci Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 165,091 shares of ABSI stock, worth $472,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

165,091

Previous 68,800 139.96%

Holding current value

$472,160

Previous $176,000 184.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.34 - $3.63 $386,312 - $599,280	165,091 New	165,091 $501,000
Q1 2025 May 15, 2025	BUY	$2.51 - $5.82 $1.42 Million - $3.3 Million	566,548 Added 146.38%	953,579 $2.39 Million
Q4 2024 Feb 14, 2025	BUY	$2.55 - $4.38 $986,929 - $1.7 Million	387,031 New	387,031 $1.01 Million
Q2 2024 Aug 14, 2024	BUY	$2.92 - $6.58 $1.3 Million - $2.94 Million	446,361 Added 111.46%	846,826 $2.61 Million
Q1 2024 May 15, 2024	BUY	$3.41 - $5.74 $1.3 Million - $2.18 Million	380,630 Added 1918.98%	400,465 $2.27 Million

Q4 2023 Feb 14, 2024	SELL	$1.15 - $4.79 $76,096 - $316,959	-66,171 Reduced 76.94%	19,835 $83,000
Q3 2023 Nov 14, 2023	BUY	$1.28 - $2.41 $20,248 - $38,123	15,819 Added 22.54%	86,006 $113,000
Q2 2023 Aug 14, 2023	BUY	$1.17 - $2.03 $44,319 - $76,896	37,880 Added 117.25%	70,187 $106,000
Q1 2023 May 15, 2023	SELL	$1.58 - $3.41 $141,081 - $304,485	-89,292 Reduced 73.43%	32,307 $56,000
Q4 2022 Feb 14, 2023	BUY	$2.0 - $3.58 $185,502 - $332,048	92,751 Added 321.52%	121,599 $255,000
Q3 2022 Nov 14, 2022	SELL	$2.95 - $4.83 $121,601 - $199,097	-41,221 Reduced 58.83%	28,848 $90,000

Others Institutions Holding ABSI

# of Institutions

153

Shares Held

70.2M

Call Options Held

701K

Put Options Held

541K

View Full List

About Absci Corp

Ticker ABSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 92,843,504
Market Cap $266M
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....

More about ABSI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account